Airsculpt Technologies, Inc. (AIRS) stock intrinsic value fair value estimate & owner earnings analysis

AirSculpt Technologies runs 31 cosmetic body-contouring centers (as of August 2026) offering its branded AirSculpt fat-removal and fat-transfer procedures. Patients pay 100% up front in cash, so there is no insurance risk, and each case brought in about $12,800 of revenue in 2025. The business depends on two things: how many patients book procedures and how much it spends on marketing and rent to win them. What has happened: revenue grew from $63 million in 2020 to $196 million in 2023 as the company opened centers, then fell to $180 million in 2024 and $152 million in 2025. Cases fell from 14,932 in 2023 to 11,852 in 2025. Volume at established centers fell 13.7% in 2024 and 22.1% in 2025, while price per case held flat. The company paused new center openings, cut about $3 million of overhead, and closed its London center in 2025. In the first half of 2026 cases were essentially flat (6,458 vs 6,468) but revenue fell 1.3%, and operating results were weaker than a year earlier in both the first and second quarters. How we measured earnings: we started from operating cash flow, took out working-capital timing swings, charged stock compensation as a real cost, and subtracted capital spending needed to keep the centers running. Because the valuation looks at the business before its lenders, we added back cash interest. On that basis the business produced about $5.2 million in 2023 and $5.6 million in 2025. 2024 was negative because $14 million was spent building new centers during a year when revenue fell, and our method counts all capital spending in a shrinking year as upkeep. We anchor on about $5.2 million a year, the median of 2023 to 2025, the only years that describe this business as a public company at roughly its current size. Earlier years were a smaller, fast-growing company that paid no entity-level income tax. Accounting choices that mattered: a $4.6 million write-off of a Salesforce software project and $2.2 million of London closing costs are non-cash and were added back. About $4.8 million a year of amortization of intangible assets from the company's earlier acquisition by its private-equity sponsor, Vesey Street Capital Partners, was also added back. We treat the decline in the brand's earning power in the forecast path, not by lowering the starting level. 2023 figures reflect the company's later revision (net loss of $4.2 million instead of $4.5 million). The company reported material weaknesses in internal controls at year-end 2025, including in lease accounting. Growth: none is credited in any case. New center openings are paused, and the earlier rollout was funded with borrowing and IPO money, not by a proven self-funded process through a downturn. Management's view that GLP-1 weight-loss drugs will raise demand for body contouring has no evidence behind it in the results, so it is left out. Year one of the base case is $4.5 million. That is below both the 2025 level and the anchor, because the first two quarters of 2026 were weaker. The most recent full year was not a growth year either: revenue fell 15.8%. The debt is the crux. The term loan was $44.2 million at June 30, 2026, at 8.39%. After repeated covenant amendments, a sponsor guarantee and a lender-engaged financial advisor, a Fourth Amendment in August 2026 moved maturity from May 11, 2027 to November 15, 2027. In exchange the company must repay $2.5 million at signing and another $2.5 million by September 30, 2026, send half of any new equity proceeds to the lenders, and report to them every two weeks on paying them off. If the loans are not repaid by October 31, 2026, it must hire investment banks. The lenders want out. The company has been selling shares steadily to cut the debt: about 2.1 million in 2025, 5.9 million in early 2026 and 0.6 million in August. The share count has risen from about 60 million to 72.1 million. We count net debt at $30.5 million: the $44.2 million loan less $11.3 million of cash above the $7.5 million minimum the lenders require, less $2.4 million raised in August. We then add the cost of replacement debt priced above our 6% yardstick. Bear case: the volume decline of 2024 to 2025 resumes. Cash earnings before interest fall to $3.5 million next year and $2.0 million by year three, then shrink 5% a year and fade out over 15 years. That is below the roughly $3.5 to $4 million annual interest bill, so refinancing comes only at about 14% or through heavy dilution or a restructuring. The business is worth about $17 million, and it owes about $43 million including the extra borrowing cost. The company would owe roughly $26 million more than it is worth, about -$0.37 per share. Base case: flat case volume holds roughly as in 2026, but earnings erode about 3% a year from $4.5 million for ten years, then fade to zero over the following ten. There is no contract or moat to rely on, only an operating record of demand of about 12,000 cases a year that is still shrinking. The loan is refinanced in late 2027 at about 11%. The business is worth about $37 million against about $37.5 million owed, so there is essentially nothing left for shareholders, about -$0.01 per share. Bull case: the 2026 stabilization in cases holds and cost cuts restore the 2025 level of about $5.6 million a year, flat for ten years, then fading out over 15 more. The debt is refinanced near today's terms at about 9%. The business is worth about $58 million against about $34 million owed, about $0.33 per share. What would make this wrong: sustained growth in cases at existing centers, which has not happened since 2023, or a refinancing well below 9% that removes the lender pressure. On the other side, a failed refinancing by late 2027 could leave shareholders with nothing. The first-half 2026 working-capital detail was not available in our data, so the quarterly trend is judged from reported revenue, operating results and cash flow totals.